# A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

> **NCT00622336** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 330 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CC-5013
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00622336
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04-01
- **Primary completion:** 2013-11-25
- **Final completion:** 2013-11-25
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2019-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00622336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00622336, "A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00622336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*